Stock listing

NYSE:ADCT ADC Therapeutics SA Stock

Home listing (NYSE) of ADC Therapeutics SA

Follow ADC Therapeutics SA into a list and get an email when it puts out news.

Share price · NYSE:ADCT

$1.28 USD -0.09 (-6.6%)

Close on Nov 20, 2026

Past year -67.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.26 – $1.36 USDNov 20, 2026
Volume
1.10M sharesNov 20, 2026
Market cap
$163.4M USDAt the close on Nov 20, 2026 · price × 127.7M shares outstanding
52-week range
$0.78 – $4.98 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$2.13M USDMedian day 1.30M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
ADC Therapeutics SA logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NYSE:ADCT · Home$1.28 USD-0.09 (-6.6%)1,095,383$1.29$1.355$1.256$1.37Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NYSE:ADCT · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.28-0.09-6.6%$1.29$1.355$1.2561,095,383
$1.37+0.02+1.5%$1.34$1.41$1.311,170,139
$1.35+0.10+8.0%$1.25$1.42$1.241,097,091
$1.25-0.09-6.7%$1.32$1.35$1.241,480,579
$1.34-0.07-5.0%$1.41$1.43$1.281,073,024
$1.41-0.19-11.9%$1.58$1.58$1.401,871,580
$1.60+0.09+6.0%$1.50$1.615$1.43767,331
$1.51-0.16-9.6%$1.62$1.73$1.4751,304,537
$1.67+0.09+5.7%$1.65$1.72$1.4052,382,657
$1.58-0.06-3.7%$1.63$1.64$1.515810,103
$1.64-0.08-4.7%$1.73$1.74$1.611,724,606
$1.72+0.17+11.0%$1.61$1.865$1.614,304,356
$1.55+0.01+0.6%$1.58$1.66$1.53865,885
$1.54+0.01+0.7%$1.58$1.675$1.501,071,483
$1.53+0.04+2.7%$1.49$1.54$1.431,175,387
$1.49-0.13-8.0%$1.67$1.70$1.49899,752
$1.62+0.03+1.9%$1.59$1.63$1.545607,765
$1.59+0.08+5.3%$1.49$1.60$1.461,250,598
$1.51+0.07+4.9%$1.45$1.54$1.431,048,540
$1.44-0.16-10.0%$1.58$1.585$1.431,045,600
$1.60+0.10+6.7%$1.50$1.62$1.479824,844
$1.50-0.02-1.3%$1.53$1.555$1.441,328,331
$1.52+0.08+5.6%$1.45$1.55$1.431,057,352
$1.44+0.04+2.9%$1.40$1.49$1.39575,619
$1.40-0.09-6.0%$1.49$1.51$1.40799,525
$1.49+0.04+2.8%$1.47$1.565$1.461,331,061
$1.45-0.25-14.7%$1.67$1.725$1.401,741,916
$1.70-0.16-8.6%$1.86$1.86$1.6253,325,278
$1.86+0.13+7.5%$1.70$1.87$1.641,593,120
$1.73+0.14+8.8%$1.58$1.83$1.563,143,187
$1.59+0.17+12.0%$1.41$1.63$1.325,552,486
$1.42+0.15+11.8%$1.25$1.44$1.2351,750,770
$1.27+0.04+3.3%$1.25$1.27$1.201,352,795
$1.23+0.10+8.8%$1.12$1.26$1.111,752,161
$1.13+0.05+4.6%$1.10$1.14$1.061,320,588
$1.08-0.14-11.5%$1.20$1.201$1.07862,274
$1.22-0.01-0.8%$1.23$1.285$1.201,111,965
$1.23-0.03-2.4%$1.27$1.29$1.20781,015
$1.26-0.01-0.8%$1.24$1.27$1.20835,119
$1.27-0.02-1.6%$1.26$1.285$1.211,076,982
$1.29-0.02-1.5%$1.305$1.31$1.241,575,647
$1.31+0.08+6.5%$1.24$1.32$1.211,972,380
$1.23+0.11+9.8%$1.13$1.25$1.121,674,295
$1.12+0.07+6.7%$1.05$1.13$1.0351,899,275
$1.05-0.01-0.9%$1.06$1.145$1.051,577,209
$1.06+0.01+1.0%$1.06$1.10$1.011,545,569
$1.05-0.04-3.7%$1.09$1.095$1.0253,316,970
$1.09-0.02-1.8%$1.12$1.12$1.031,259,823
$1.11+0.04+3.7%$1.07$1.12$1.06808,479
$1.07-0.04-3.6%$1.13$1.156$1.04989,105
$1.11-0.11-9.0%$1.21$1.24$1.07957,194
$1.22-0.08-6.2%$1.28$1.31$1.1911,709,284
$1.30-0.06-4.4%$1.33$1.35$1.27930,761
$1.36+0.04+3.0%$1.30$1.37$1.301,478,303
$1.320.000.0%$1.32$1.37$1.302,774,762
$1.32+0.08+6.5%$1.23$1.35$1.231,955,644
$1.24+0.07+6.0%$1.15$1.24$1.141,149,641
$1.17+0.03+2.6%$1.13$1.19$1.1251,251,778
$1.14+0.02+1.8%$1.11$1.17$1.072,577,910
$1.12+0.07+6.7%$1.05$1.14$1.051,403,771
$1.05+0.01+1.0%$1.04$1.075$1.011,947,239
$1.04+0.075+7.8%$0.976$1.05$0.963,927,974
$0.965-0.032-3.2%$0.99$1.00$0.951640,512
$0.997+0.037+3.8%$0.974$1.00$0.971,088,237
$0.96-0.08-7.7%$1.02$1.04$0.952,422,878
Ticker
NYSE:ADCT
Asset type
Stock
Exchange
NYSE
Currency
USD

What changed lately

Latest news

All ADC Therapeutics SA news

ADC Therapeutics SA on 6ix

News releases
25 in the last 12 months · 45 in all · newest Nov 9, 2026 · oldest 2025
Calls
25 calls with a replay · 25 with a transcript · latest Aug 13, 2026
Decks
40 decks · latest Nov 4, 2026

Where ADC Therapeutics SA is listed

ListingExchangeCountryCurrency
NYSE:ADCT · Home listing · This pageNYSEUnited StatesUSD
BOATS:ADCTBOATSUnited StatesUSD

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$17.99M USD
P/E
Loss
EV/sales
−0.2×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
86.8%
Operating margin
−97.7%
Net margin
−95.7%
Debt to equity
Negative equity
Beta vs S&P 500
1.49

Forecasts

3 strong buy · 2 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
3.33 USD · Analysts' mean
EPS, year to Dec 2026
-0.75 · 4 analysts
Revenue, year to Dec 2026
80.56M · 5 analysts

Team and board

Officers

OfficerRole
Ameet MallikChief Executive Officer
Jose CarmonaChief Financial Officer
Peter GrahamChief Legal Officer
David EgeChief Technical Officer
Kimberly PopeChief People Officer
Kristen Harrington-SmithChief Commercial Officer
Mohamed ZakiChief Medical Officer

Board

DirectorRole
Ron SquarerChairman
Bob AzelbyNon-Executive Director
Jean-Pierre BizzariNon-Executive Director
Peter HugVice-Chairman and Lead Independent Director
Tim CoughlinNon-Executive Director
Tyrell J. RiversNon-Executive Director
Victor SandorNon-Executive Director
Viviane MongesNon-Executive Director

Events

Next results
Mar 10, 2027 (expected)

Calls

CallWhenStatus
ADC Therapeutics (NYSE:ADCT) Q2 2026 Earnings CallThu, Aug 13, 2026 · 8:30 AM ETReplay
ADC Therapeutics (NYSE:ADCT) Q1 2026 Earnings CallMon, May 04, 2026 · 8:30 AM ETReplay
ADC Therapeutics (NYSE:ADCT) Q4 2025 Earnings CallTue, Mar 10, 2026 · 8:30 AM ETReplay
ADC Therapeutics (NYSE:ADCT) Q3 2025 Earnings CallMon, Nov 10, 2025 · 8:30 AM ETReplay
ADC Therapeutics (NYSE:ADCT) Q2 2025 Earnings CallTue, Aug 12, 2025 · 8:30 AM ETReplay
ADC Therapeutics (NYSE:ADCT) Q1 2025 Earnings CallWed, May 14, 2025 · 8:30 AM ETReplay
ADC Therapeutics (NYSE:ADCT) Q4 2024 Earnings CallThu, Mar 27, 2025 · 8:30 AM ETReplay
ADC Therapeutics (NYSE:ADCT) Q3 2024 Earnings CallThu, Nov 07, 2024 · 8:30 AM ETReplay
ADC Therapeutics (NYSE:ADCT) Q2 2024 Earnings CallTue, Aug 06, 2024 · 8:30 AM ETReplay
ADC Therapeutics (NYSE:ADCT) Q1 2024 Earnings CallMon, May 06, 2024 · 8:30 AM ETReplay
All 25 calls
CallWhenStatus
ADC Therapeutics (NYSE:ADCT) Q4 2023 Earnings CallWed, Mar 13, 2024 · 8:30 AM ETReplay
ADC Therapeutics (NYSE:ADCT) Q3 2023 Earnings CallTue, Nov 07, 2023 · 8:30 AM ETReplay
ADC Therapeutics (NYSE:ADCT) Q2 2023 Earnings CallTue, Aug 08, 2023 · 8:30 AM ETReplay
ADC Therapeutics (NYSE:ADCT) Q1 2023 Earnings CallTue, May 09, 2023 · 8:30 AM ETReplay
ADC Therapeutics (NYSE:ADCT) Q4 2022 Earnings CallTue, Feb 28, 2023 · 8:30 AM ETReplay
ADC Therapeutics (NYSE:ADCT) Q3 2022 Earnings CallTue, Nov 08, 2022 · 8:30 AM ETReplay
ADC Therapeutics (NYSE:ADCT) Q2 2022 Earnings CallTue, Aug 09, 2022 · 8:30 AM ETReplay
ADC Therapeutics (NYSE:ADCT) Q1 2022 Earnings CallMon, May 09, 2022 · 8:30 AM ETReplay
ADC Therapeutics (NYSE:ADCT) Q4 2021 Earnings CallThu, Mar 03, 2022 · 8:30 AM ETReplay
ADC Therapeutics (NYSE:ADCT) Q3 2021 Earnings CallTue, Nov 02, 2021 · 8:30 AM ETReplay
ADC Therapeutics (NYSE:ADCT) Q2 2021 Earnings CallTue, Aug 03, 2021 · 8:30 AM ETReplay
ADC Therapeutics (NYSE:ADCT) Q1 2021 Earnings CallThu, May 06, 2021 · 8:30 AM ETReplay
ADC Therapeutics (NYSE:ADCT) Q4 2020 Earnings CallThu, Mar 18, 2021 · 8:30 AM ETReplay
ADC Therapeutics (NYSE:ADCT) Q3 2020 Earnings CallThu, Nov 12, 2020 · 8:30 AM ETReplay
ADC Therapeutics (NYSE:ADCT) Q2 2020 Earnings CallTue, Aug 18, 2020 · 8:30 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 9, 2026 · Before open+5.7%
Q2 2026Aug 13, 2026 · Before open−14.6%
Q1 2026May 4, 2026 · Before open−3.9%
Q4 2025Mar 12, 2026−15.4%
Q3 2025Nov 10, 2025 · Before open+4.2%
Q2 2025Aug 12, 2025 · Before open+9.7%
Q1 2025May 5, 2025 · Before open−1.4%
Q4 2024Mar 27, 2025 · Before open−3.8%
Q3 2024Nov 7, 2024 · Before open−8.4%
Q2 2024Aug 6, 2024 · Before open+1.7%
All 20 quarters
QuarterResultsShare move
Q1 2024May 6, 2024 · Before open−9.2%
Q4 2023Mar 13, 2024 · Before open−12.4%
Q3 2023Nov 7, 2023 · Before open−16.0%
Q2 2023Aug 8, 2023 · Before open+11.9%
Q1 2023May 9, 2023 · Before open+2.4%
Q4 2022Feb 28, 2023 · Before open−11.6%
Q3 2022Nov 8, 2022 · Before open−2.8%
Q2 2022Aug 9, 2022 · Before open−1.0%
Q1 2022May 9, 2022 · Before open−28.7%
Q4 2021Mar 3, 2022 · Before open−8.9%

Open Events

Decks

DeckKindSlidesDate
Corporate Update (November 2026)Corporate update18 slidesNov 4, 2026
Investor Presentation (November 2026)Investor deck25 slidesNovember 2026
Q2 2026 Earnings PresentationEarnings9 slidesAug 13, 2026
Investor Presentation (August 2026)Investor deck62 slidesAugust 2026
Technical Presentation (June 2026)Technical29 slidesJun 3, 2026
Q1 2026 Earnings PresentationEarnings9 slidesMay 4, 2026
Q4 2025 Earnings PresentationEarnings15 slidesMar 10, 2026
Investor Presentation (January 2026)Investor deck28 slidesJan 12, 2026
Q3 2025 Earnings PresentationEarnings13 slidesNov 10, 2025
Investor Presentation (October 2025)Investor deck28 slidesOct 14, 2025
All 40 decks
DeckKindSlidesDate
Investor Presentation (September 2025)Investor deck27 slidesSep 30, 2025
Q2 2025 Earnings PresentationEarnings23 slidesAug 12, 2025
Q1 2025 Earnings PresentationEarnings13 slidesMay 14, 2025
Q4 2024 Earnings PresentationEarnings10 slidesMar 27, 2025
JPMorgan 43rd Annual Healthcare Conference 2025Conference26 slidesJan 13, 2025
Q3 2024 Earnings PresentationEarnings11 slidesNov 7, 2024
Q2 2024 Earnings PresentationEarnings13 slidesAug 6, 2024
Investor Presentation (May 2024)Investor deck32 slidesMay 14, 2024
Corporate Update (May 2024)Corporate update13 slidesMay 6, 2024
Q1 2024 Earnings PresentationEarnings22 slidesMay 6, 2024
Technical Presentation (April 2024)Technical65 slidesApr 9, 2024
Q4 2023 Earnings PresentationEarnings21 slidesMar 13, 2024
Cowen Conference 2024Conference14 slidesMar 5, 2024
Corporate Update (January 2024)Corporate update26 slidesJan 4, 2024
Q3 2023 Earnings PresentationEarnings12 slidesNov 7, 2023
Morgan Stanley Global Healthcare Conference 2023Conference21 slidesSep 11, 2023
Q2 2023 Earnings PresentationEarnings12 slidesAug 8, 2023
Q1 2023 Earnings PresentationEarnings13 slidesMay 9, 2023
Q4 2022 Earnings PresentationEarnings15 slidesFeb 28, 2023
J.P. Morgan Healthcare Conference 2023Conference22 slidesJan 9, 2023
Q3 2022 Earnings PresentationEarnings11 slidesNov 8, 2022
Q2 2022 Earnings PresentationEarnings12 slidesAug 9, 2022
Q1 2022 Earnings PresentationEarnings12 slidesMay 9, 2022
Q4 2021 Earnings PresentationEarnings11 slidesMar 3, 2022
Q3 2021 Earnings PresentationEarnings10 slidesNov 2, 2021
Q2 2021 Earnings PresentationEarnings11 slidesAug 3, 2021
Q1 2021 Earnings PresentationEarnings14 slidesMay 6, 2021
Q4 2020 Earnings PresentationEarnings11 slidesMar 18, 2021
62nd ASH Annual Meeting and Exposition 2020Conference11 slidesDec 6, 2020
Technical Presentation (December 2018)Technical19 slidesDecember 2018

Open Decks

Financings

RaiseDate
Private placement of common shares and pre-funded warrants
Announced: US$86.6M · US$1.42 a share · Jefferies +2
Dealers: Jefferies, Guggenheim Securities, Cantor
Buyers: Bain Capital Life Sciences; Redmile; TCGX; Nantahala Capital
Use of proceeds: Fund ZYNLONTA pipeline studies including Phase 3 trials in DLBCL and MZL, strengthen the balance sheet, working capital and general corporate purposes
Oct 8, 2026
Private placement of equity securities
Closed: US$60M raised · US$4 a share · Jefferies
Dealers: Jefferies (lead)
Buyers: TCGX; Redmile Group
Use of proceeds: Fund the commercial expansion of ZYNLONTA and strengthen the balance sheet
Nov 10, 2025
Private placement of common shares and pre-funded warrants
Announced: US$100M · US$3.53 a share · Jefferies +3
Dealers: Jefferies, Guggenheim Securities, Cantor, RBC Capital Markets
Buyers: Redmile Group (led the PIPE)
Use of proceeds: ZYNLONTA clinical development and commercialization, working capital and general corporate purposes
Jun 12, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$19.00 a share on May 14, 2020.

Price
US$19.00 a share
Shares offered
12,245,631 common shares
Offering size
US$232.7 million
Underwriters' option
Up to 1,836,844 more shares
Listing
ADCT on the New York Stock Exchange
Underwriters
MORGAN STANLEY, BofA SECURITIES, COWEN · In the order on the cover
Shares delivered
On or about May 19, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceMar 2, 2020
Filed publiclyApr 24, 2020
Amended 3 timesNewest May 14, 2020
Shares registered with an exchangeMay 11, 2020
Declared effective by the SECMay 14, 2020
Final prospectus, with the priceMay 18, 2020

Open IPO · From the cover of the final prospectus (424B4) filed May 18, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue81.4M70.8M69.6M209.9M33.9M02.34M1.14M1.80M
Cost of revenue5.80M5.95M2.53M3.30M1.39M141.8M107.5M118.1M85.5M
Gross profit73.7M64.9M67.0M206.6M32.5M-141.8M2.34M-116.9M-83.7M
Research and development104.0M109.6M127.1M186.5M158.0M142.0M107.5M118.3M85.5M
Selling, general and administrative36.6M64.5M72.9M107.7M71.5M55.1M14.2M8.60M7.81M
Operating income-121.5M-130.7M-166.0M-123.3M-261.7M-219.3M-119.4M-125.9M-91.7M
Depreciation and amortization705.0K1.33M1.19M1.06M2.63M1.97M1.65M740.0K341.0K
EBITDA-120.8M-129.3M-164.8M-122.3M-259.1M-217.3M-117.8M-125.2M-91.3M
Interest expense51.6M50.2M46.3M36.7M18.3M4.93M156.0K3.28M2.68M
Income before tax-141.6M-156.1M-195.4M-146.8M-251.5M-246.0M-115.9M-122.9M-89.8M
Income tax1.01M166.0K39.1M227.0K-21.5M327.0K582.0K224.0K48.0K
Net income-142.6M-157.8M-240.1M-157.1M-230.0M-246.3M-116.5M-123.1M-89.9M
Earnings per share, basic-1.12-1.62-2.94-2.01-3.00-3.77-1.74-2.29-1.53
Earnings per share, diluted-1.12-1.62-2.94-2.01

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents261.3M250.9M278.6M326.4M466.5M439.2M115.6M138.8M262.8M143.7M
Receivables29.1M20.3M25.2M73.0M31.1M2.69M2.84M372.0K1.93M5.91M
Inventory4.18M2.25M16.2M12.1M11.1M6.50M2.47M1.20M293.0K
Current assets306.3M291.3M336.3M435.0M525.2M450.4M122.6M142.1M265.2M151.3M
Property, plant and equipment05.08M5.62M3.35M11.2M4.76M6.27M1.54M1.14M
Total assets323.1M322.0M354.8M490.9M618.0M513.7M137.7M150.6M271.9M155.1M
Accounts payable9.18M18.0M15.6M12.4M12.1M5.28M3.33M6.75M7.62M2.15M
Current liabilities70.2M80.5M67.7M81.9M73.9M40.4M19.9M22.4M20.5M9.67M
Long-term debt112.5M113.6M112.7M97.2M125.1M108.0M
Total debt3.00M0124.4M129.8M139.7M115.1M5.03M
Total liabilities509.0M524.6M503.0M411.4M451.9M178.2M26.5M24.3M22.8M14.2M
Shareholders' equity-185.8M-202.6M-148.2M79.5M166.1M335.5M111.2M126.2M249.2M140.9M
Shares outstanding125.7M98.9M82.3M80.6M76.7M65.4M66.9M53.8M58.9M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-141.2M-123.8M-118.7M-138.3M-233.4M-168.7M-121.6M-121.4M-74.9M
Capital spending-264.0K-867.0K-3.22M-687.0K-6.38M-2.81M-2.15M-2.47M-3.16M
Free cash flow-141.4M-124.7M-121.9M-139.0M-239.8M-171.5M-123.7M-123.8M-78.1M
Cash from investing395.0K-867.0K-3.22M-687.0K-6.67M-2.83M-2.25M-2.51M-3.25M
Cash from financing150.9M97.1M73.9M-897.0K267.4M495.0M100.5M-24.0K197.2M
Share buybacks-221.0K00-141.0K-24.0K197.2M
Change in cash10.2M-27.6M-48.0M-139.9M27.3M323.6M-23.3M-123.9M119.1M

Open Financials

Filings

FilingDateTypeFiled with
EFFECT · Notice that a registration is effectiveNov 20, 2026Other filingsSEC
424B3 · ProspectusNov 19, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2026Big-stake noticeSEC
S-3 · Registration statementNov 9, 2026Offer documentSEC
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
8-K · Current reportNov 9, 2026ResultsSEC
8-K · Current reportNov 4, 2026ResultsSEC
S-4 · Registration statementNov 3, 2026Offer documentSEC
SCHEDULE 13G · Big-stake noticeOct 29, 2026Big-stake noticeSEC
8-K · Current reportOct 13, 2026ResultsSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansAug 13, 2026Offer documentSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportAug 13, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 27, 2026Big-stake noticeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
8-K · Current reportJul 2, 2026Management or board changeSEC
8-K · Current reportJun 24, 2026Current reportSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
8-K · Current reportJun 3, 2026Current reportSEC
8-K · Current reportJun 2, 2026Meeting outcomeSEC
10-Q · Quarterly reportMay 4, 2026Quarterly reportSEC
8-K · Current reportMay 4, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 24, 2026Big-stake noticeSEC
DEFA14A · Additional proxy materialApr 20, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 20, 2026Meeting noticeSEC
424B3 · ProspectusApr 15, 2026Offer documentSEC
PRE 14A · Preliminary proxy statementApr 10, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 6, 2026Big-stake noticeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveMar 17, 2026Other filingsSEC
424B3 · ProspectusMar 16, 2026Offer documentSEC
CORRESP · Letter to the SECMar 12, 2026Other filingsSEC
UPLOAD · Letter from the SECMar 12, 2026Other filingsSEC
S-3 · Registration statementMar 10, 2026Offer documentSEC
ARS · Annual report to shareholdersMar 10, 2026Annual reportSEC
10-K · Annual reportMar 10, 2026Annual reportSEC
8-K · Current reportMar 10, 2026ResultsSEC
8-K · Current reportFeb 23, 2026Material contractSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
8-K · Current reportJan 12, 2026Current reportSEC
8-K · Current reportJan 8, 2026ResultsSEC
EFFECT · Notice that a registration is effectiveDec 15, 2025Other filingsSEC
424B3 · ProspectusDec 12, 2025Offer documentSEC
CORRESP · Letter to the SECDec 10, 2025Other filingsSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
S-3/A · Registration statement, amendedDec 9, 2025Offer documentSEC
8-K · Current reportDec 5, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2025Big-stake noticeSEC
S-3 · Registration statementNov 10, 2025Offer documentSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
8-K · Current reportNov 10, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2025Big-stake noticeSEC
4 · Change in ownershipOct 28, 2025Insider tradeSEC
8-K · Current reportOct 14, 2025ResultsSEC
S-8 · Registration statement for employee plansSep 30, 2025Offer documentSEC
8-K · Current reportSep 30, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
S-8 · Registration statement for employee plansAug 12, 2025Offer documentSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
424B3 · ProspectusJul 10, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveJul 10, 2025Other filingsSEC
CORRESP · Letter to the SECJul 7, 2025Other filingsSEC
UPLOAD · Letter from the SECJul 7, 2025Other filingsSEC
S-3 · Registration statementJun 30, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeJun 17, 2025Big-stake noticeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
8-K · Current reportJun 12, 2025Material contractSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 5, 2025Insider tradeSEC
3/A · Initial statement of ownership, amendedJun 5, 2025Insider tradeSEC
8-K · Current reportJun 5, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 19, 2025Big-stake noticeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025ResultsSEC
4 · Change in ownershipMay 8, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 24, 2025Big-stake noticeSEC
DEF 14A · Proxy statementApr 21, 2025Meeting noticeSEC
DEFA14A · Additional proxy materialApr 21, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 9, 2025Meeting noticeSEC
ARS · Annual report to shareholdersMar 27, 2025Annual reportSEC
10-K · Annual reportMar 27, 2025Annual reportSEC
8-K · Current reportMar 27, 2025ResultsSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 3, 2025Big-stake noticeSEC
8-K · Current reportJan 13, 2025ResultsSEC
4 · Change in ownershipDec 13, 2024Insider tradeSEC
4 · Change in ownershipDec 9, 2024Insider tradeSEC
4 · Change in ownershipDec 9, 2024Insider tradeSEC
4 · Change in ownershipDec 9, 2024Insider tradeSEC
4 · Change in ownershipDec 9, 2024Insider tradeSEC
4 · Change in ownershipDec 9, 2024Insider tradeSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
8-K · Current reportNov 13, 2024Meeting outcomeSEC
SC 13G/A · Big-stake notice, amendedNov 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 13, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
DEFA14A · Additional proxy materialSep 23, 2024Meeting noticeSEC
DEF 14A · Proxy statementSep 23, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementSep 13, 2024Meeting noticeSEC
EFFECT · Notice that a registration is effectiveAug 14, 2024Other filingsSEC
CORRESP · Letter to the SECAug 9, 2024Other filingsSEC
UPLOAD · Letter from the SECAug 9, 2024Other filingsSEC
S-3 · Registration statementAug 6, 2024Offer documentSEC
10-Q · Quarterly reportAug 6, 2024Quarterly reportSEC
8-K · Current reportAug 6, 2024ResultsSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
144 · Notice of proposed saleJun 18, 2024Other filingsSEC
144 · Notice of proposed saleJun 18, 2024Other filingsSEC
144 · Notice of proposed saleJun 18, 2024Other filingsSEC
144 · Notice of proposed saleJun 18, 2024Other filingsSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
8-K · Current reportJun 14, 2024Meeting outcomeSEC
3 · Initial statement of ownershipJun 6, 2024Insider tradeSEC
3 · Initial statement of ownershipJun 6, 2024Insider tradeSEC
8-K · Current reportMay 14, 2024Current reportSEC
4 · Change in ownershipMay 10, 2024Insider tradeSEC
4 · Change in ownershipMay 9, 2024Insider tradeSEC
8-K · Current reportMay 8, 2024Current reportSEC
144 · Notice of proposed saleMay 7, 2024Other filingsSEC
424B5 · ProspectusMay 7, 2024Offer documentSEC
424B5 · ProspectusMay 6, 2024Offer documentSEC
10-Q · Quarterly reportMay 6, 2024Quarterly reportSEC
8-K · Current reportMay 6, 2024ResultsSEC
SC 13G · Big-stake noticeMay 3, 2024Big-stake noticeSEC
DEFA14A · Additional proxy materialApr 26, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 26, 2024Meeting noticeSEC
SC 13D/A · Big-stake notice, amendedApr 25, 2024Big-stake noticeSEC
PRE 14A · Preliminary proxy statementApr 16, 2024Meeting noticeSEC
8-K · Current reportApr 9, 2024Current reportSEC
424B3 · ProspectusMar 15, 2024Offer documentSEC
424B3 · ProspectusMar 15, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveMar 15, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveMar 15, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveMar 15, 2024Other filingsSEC
POS AM · Amendment to an effective registrationMar 13, 2024Offer documentSEC
POS AM · Amendment to an effective registrationMar 13, 2024Offer documentSEC
POS AM · Amendment to an effective registrationMar 13, 2024Offer documentSEC
ARS · Annual report to shareholdersMar 13, 2024Annual reportSEC
10-K · Annual reportMar 13, 2024Annual reportSEC
8-K · Current reportMar 13, 2024ResultsSEC
8-K · Current reportMar 5, 2024Current reportSEC
8-K · Current reportFeb 29, 2024Management or board changeSEC

This page holds 200 of 444 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from ADC Therapeutics SA’s releases · as of Oct 8, 2026

Common shares
127,667,695
Fully diluted
127,667,695

Fully diluted

LineShares
Common shares127,667,695

Share count over time

CountShares
Nov 22, 2026127,667,695

Open Cap table

Shareholders

Funds

HolderSharesValueChangeAs of
iShares Russell 2000 ETF2.74MUS$2.93M+279KJun 30, 2026
Fidelity Small Cap Index Fund1.15MUS$1.21M+149KJul 31, 2026
iShares Russell 2000 Value ETF742KUS$794KNewJun 30, 2026
iShares Biotechnology ETF669KUS$716K−4,200Jun 30, 2026
Vanguard Russell 2000 Index Fund524KUS$1.78M+97,305May 31, 2026
iShares Micro-Cap ETF360KUS$386K+103KJun 30, 2026
Vanguard U.S. Momentum Factor ETF317KUS$1.08M+203May 31, 2026
Schwab Small-Cap Index Fund259KUS$272K+34,326Jul 31, 2026
iShares Russell 2000 Growth ETF203KUS$217K−627KJun 30, 2026
Small Company Growth Portfolio177KUS$189K+64,924Jun 30, 2026
Show 50 holders
HolderSharesValueChangeAs of
Master Small Cap Index Series173KUS$186KNo changeJun 30, 2026
Nuveen Small Cap Blend Index Fund153KUS$160K+30,435Jul 31, 2026
Fidelity Small Cap Value Index Fund116KUS$124KNewJun 30, 2026
VIP Disciplined Small Cap Portfolio111KUS$119K+41,209Jun 30, 2026
EQ/2000 Managed Volatility Portfolio104KUS$112KNo changeJun 30, 2026
Vanguard Russell 2000 Growth Index Fund95,226US$324K+16,236May 31, 2026
Clearwater Select Equity Fund79,373US$84,929+63,129Jun 30, 2026
State Street(R) SPDR(R) S&P(R) International Small Cap ETF78,102US$83,569+809Jun 30, 2026
LVIP State Street Small-Cap Index Fund53,800US$57,566No changeJun 30, 2026
Global X Russell 2000 ETF51,103US$53,658+6,865Jul 31, 2026
EQ/AB Small Cap Growth Portfolio49,840US$53,329+33,310Jun 30, 2026
EQ/Small Company Index Portfolio49,840US$53,329+33,310Jun 30, 2026
iShares Russell 3000 ETF47,041US$50,334−364Jun 30, 2026
Small Cap Index Fund43,766US$46,830−4,425Jun 30, 2026
Small Cap Index Fund42,246US$144K+6,998May 31, 2026
State Street Small/Mid Cap Equity Index Portfolio34,700US$37,129No changeJun 30, 2026
AQR Small Cap Momentum Style Fund30,255US$113KFirst reportMar 31, 2026
ATM Small Cap Managed Volatility Portfolio29,928US$32,023No changeJun 30, 2026
Small-Cap Index Portfolio26,855US$28,735No changeJun 30, 2026
1290 VT Micro Cap Portfolio24,276US$25,975+6,027Jun 30, 2026
iShares Russell Small/Mid-Cap Index Fund23,314US$24,480+11,310Jul 31, 2026
U.S. Small Cap Equity Fund21,617US$23,130+2,943Jun 30, 2026
NVIT Small Cap Index Fund20,514US$21,950No changeJun 30, 2026
Fidelity Small Cap Growth Index Fund20,505US$21,940−57,133Jun 30, 2026
Bridge Builder Small/Mid Cap Growth Fund19,177US$20,519No changeJun 30, 2026
DWS Small Cap Index VIP18,596US$19,898+4,348Jun 30, 2026
T. Rowe Price Small-Cap Index Fund16,432US$17,582+4,813Jun 30, 2026
iShares Total U.S. Stock Market Index Fund13,438US$14,110No changeJul 31, 2026
1290 VT Small Cap Value Portfolio13,186US$14,109NewJun 30, 2026
U.S. Small Cap Equity Fund11,857US$12,450−60,437Jul 31, 2026
BlackRock Small Cap Index V.I. Fund11,430US$12,230No changeJun 30, 2026
SA Small Cap Index Portfolio10,003US$10,503No changeJul 31, 2026
Vanguard Russell 3000 Index Fund9,269US$31,515+3,131May 31, 2026
Nationwide Small Cap Index Fund8,122US$8,528No changeJul 31, 2026
Siit Extended Market Index Fund8,000US$27,200No changeMay 31, 2026
Nationwide Fundamental All Cap Equity Portfolio7,557US$7,935NewJul 31, 2026
SmallCap Value Fund II6,990US$7,340NewJul 31, 2026
CVT Russell 2000 Small Cap Index Portfolio6,859US$7,339No changeJun 30, 2026
Venerable Small Cap Index Fund6,000US$6,420No changeJun 30, 2026
PD Small-Cap Value Index Portfolio5,372US$5,748NewJun 30, 2026

This page holds 50 of 77 holders. Open Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
RedCo II Master Fund, L.P.
10% owner
Sale2,634,506USD 3.28US$8.64MApr 2, 2026
RedCo II Master Fund, L.P.
10% owner
Sale2,529,491USD 3.28US$8.3MApr 2, 2026
RedCo II Master Fund, L.P.
10% owner
Sale169,265USD 3.80US$643KApr 1, 2026
RedCo II Master Fund, L.P.
10% owner
Sale162,517USD 3.80US$618KApr 1, 2026
RedCo II Master Fund, L.P.
10% owner
Sale196,229USD 3.75US$736KMar 31, 2026
RedCo II Master Fund, L.P.
10% owner
Sale188,407USD 3.75US$707KMar 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Robert Azelby
Other companies: Tango Therapeutics, Inc. (Chairman; Former President and CEO, Eliem Therapeutics, Inc. · Since at least Jun 19, 2026); Autolus Therapeutics plc (Member of the Audit Committee, Member of the Nominating and Governance Committee · Since at least Mar 18, 2026); Terns Pharmaceuticals, Inc. (Director · Since at least Feb 20, 2025); Cardinal Health, Inc. (Director · Since at least Mar 1, 2024); Aduro Biotech Inc (Director · Apr 10, 2023 – Aug 11, 2023 · Past); Climb Bio, Inc. (President & CEO, Director · Aug 9, 2021 – Oct 31, 2022 · Past); Immunomedics Inc (Director · Feb 26, 2020 – Oct 23, 2020 · Past); Clovis Oncology Inc (Director · Oct 11, 2018 – Jun 10, 2021 · Past); Alder BioPharmaceuticals Inc (President and CEO, Director · Jun 13, 2018 – Oct 22, 2019 · Past); Cascadian Therapeutics Inc (Director · Mar 31, 2017 – Mar 9, 2018 · Past); Juno Therapeutics Inc (EVP & Chief Commercial Officer · Nov 1, 2015 – Mar 5, 2018 · Past)
Director · Since at least Jan 2, 2024
Timothy P. Coughlin
Other companies: Vir Biotechnology, Inc. (Director · Since at least Jun 9, 2026); aTyr Pharma, Inc. (Chairman · Since at least Apr 7, 2017); Travere Therapeutics, Inc. (Director · Since at least Mar 31, 2015); Fate Therapeutics, Inc. (Director · Sep 30, 2013 – Jun 7, 2024 · Past); Neurocrine Biosciences, Inc. (Chief Financial Officer · Sep 18, 2006 – Feb 6, 2017 · Past)
Director · Since at least Jun 3, 2025
Jean-Pierre Bizzari
Other companies: Aprea Therapeutics, Inc. (Director · Since at least Aug 23, 2023); Palvella Therapeutics, Inc. (Director · Jun 29, 2015 – Jan 25, 2020 · Past); Celator Pharmaceuticals Inc (Director · Feb 27, 2015 – Jul 12, 2016 · Past); Halozyme Therapeutics, Inc. (Director · Jan 17, 2015 – May 5, 2023 · Past)
Non-Executive Director · Since at least Jan 2, 2024
Ron Squarer
Other companies: Nuvalent, Inc. (Director · Since at least Dec 10, 2025); Travere Therapeutics, Inc. (Director · Since at least Apr 10, 2017); Deciphera Pharmaceuticals LLC (Director · Dec 4, 2019 – Jun 11, 2024 · Past); Hospira Inc (Chief Commercial Officer · Jan 7, 2009 – Feb 24, 2011 · Past)
Director · Since at least Jan 2, 2024
Jose Carmona
Other companies: Rubius Therapeutics Inc (Chief Financial Officer · Oct 1, 2020 – Jan 31, 2022 · Past); Radius Health, Inc. (Chief Financial Officer · May 15, 2017 – Feb 26, 2020 · Past); Innocoll AG (CFO · Jan 1, 2017 – Jan 1, 2017 · Past)
Chief Financial Officer · Since at least Jan 2, 2024
Peter Graham
Other companies: Antares Pharma Inc (See Remarks · Jul 14, 2015 – May 24, 2022 · Past); Delcath Systems, Inc. (EVP; General Counsel · Apr 20, 2010 – Nov 14, 2013 · Past); AngioDynamics, Inc. (Director · Jan 16, 2006 – Oct 25, 2006 · Past)
Chief Legal Officer · Since at least Jan 2, 2024
Tyrell J. Rivers
Other companies: Viela Bio Inc (Director · Oct 2, 2019 – Mar 15, 2021 · Past); PhaseBio Pharmaceuticals Inc (Director · Oct 17, 2018 – Oct 17, 2018 · Past); G1 Therapeutics Inc (Director · May 16, 2017 – May 16, 2017 · Past)
Non-Executive Director · Since at least Jan 2, 2024
Victor Sandor
Other companies: AbCellera Biologics Inc. (Director · Since at least Jun 1, 2026); Kymera Therapeutics, Inc. (Director · Since at least Nov 3, 2022); Prelude Therapeutics Incorporated (Director · Since at least Sep 24, 2020)
Non-Executive Director · Since at least Jan 2, 2024
Ameet Mallik
Other companies: Atara Biotherapeutics, Inc. (Director · Since at least Aug 9, 2021); Rafael Holdings, Inc. (Director · May 1, 2021 – Feb 1, 2022 · Past)
Chief Executive Officer · Since at least Jan 2, 2024
Ron Squarer
Other companies: Travere Therapeutics, Inc. (Director · Since at least May 21, 2026); Nuvalent, Inc. (Director · Since at least Dec 10, 2025)
Chairman · Since at least Jun 3, 2026
All 20 people
PersonSeat
Viviane Monges
Other companies: Pharvaris N.V. (Director, Audit Chair · Since at least Mar 17, 2026); DBV Technologies SA (Director · Jan 1, 2021 – Jun 10, 2021 · Past)
Non-Executive Director · Since at least Jan 2, 2024
Tim Coughlin
Other companies: Travere Therapeutics, Inc. (Director · Since at least Jun 16, 2026)
Non-Executive Director · Since at least Jun 3, 2026
Bob AzelbyNon-Executive Director · Since at least Jun 3, 2026
David EgeChief Technical Officer · Since at least Nov 5, 2026
Kimberly PopeChief People Officer · Since at least Nov 5, 2026
Kristen Harrington-SmithChief Commercial Officer · Since at least Nov 5, 2026
Lisa Michelle KalleboChief Accounting Officer · Since at least Jan 2, 2024
Mohamed ZakiChief Medical Officer · Since at least Jan 2, 2024
Peter HugVice-Chairman and Lead Independent Director · Since at least Jan 2, 2024
Thomas PfistererDirector · Jan 2, 2024 – Jun 17, 2024 · Past

Open People

Log in to ask 6ix AI your own questions about ADC Therapeutics SA.